Altered immune response differentially enhances susceptibility to Cryptococcus neoformans and Cryptococcus gattii infection in mice expressing the HIV-1 transgene

Infection and Immunity

Volumn 81, Issue 4, 2013, Pages 1100-1113

  Leongson, Kassandre ^a   Cousineau Côté, Vincent ^a   Goupil, Mathieu ^a   Aumont, Francine ^a   Sénéchal, Serge ^a   Gaboury, Louis ^a   Jolicoeur, Paul ^a,b,c   Kronstad, James W ^d   de Repentigny, Louis ^a  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^b UNIVERSITY OF MONTREAL   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; CRYPTOCOCCOSIS; CRYPTOCOCCUS GATTII; CRYPTOCOCCUS NEOFORMANS; FEMALE; FUNGAL STRAIN; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; INFLAMMATORY CELL; LIVER; LUNG; LUNG PARENCHYMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN; TRANSGENE;

ANIMALS; COLONY COUNT, MICROBIAL; CRYPTOCOCCUS GATTII; CRYPTOCOCCUS NEOFORMANS; DISEASE MODELS, ANIMAL; DISEASE SUSCEPTIBILITY; HISTOCYTOCHEMISTRY; HIV-1; LIVER; LUNG; MICE; MICE, TRANSGENIC; SPLEEN; SURVIVAL ANALYSIS;

EID: 84875497741     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.01339-12     Document Type: Article

References (77)

1. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. 2009. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 23:525-530.
2. Bodasing N, Seaton RA, Shankland GS, Kennedy D. 2004. Cryptococcus neoformans var. gattii meningitis in an HIV-positive patient: first observation in the United Kingdom. J. Infect. 49:253-255.
3. Chaturvedi S, Dyavaiah M, Larsen RA, Chaturvedi V. 2005. Cryptococcus gattii in AIDS patients, southern California. Emerg. Infect. Dis. 11: 1686-1692.
4. Hoang LM, Maguire JA, Doyle P, Fyfe M, Roscoe DL. 2004. Cryptococcus neoformans infections at Vancouver Hospital and Health Sciences Centre (1997-2002): epidemiology, microbiology and histopathology. J. Med. Microbiol. 53:935-940.
5. Karstaedt AS, Crewe-Brown HH, Dromer F. 2002. Cryptococcal meningitis caused by Cryptococcus neoformans var. gattii, serotype C, in AIDS patients in Soweto, South Africa. Med. Mycol. 40:7-11.
6. Morgan J, McCarthy KM, Gould S, Fan K, Arthington-Skaggs B, Iqbal N, Stamey K, Hajjeh RA, Brandt ME, Gauteng Cryptococcal Surveillance Initiative Group. 2006. Cryptococcus gattii infection: characteristics and epidemiology of cases identified in a South African province with high HIV seroprevalence, 2002-2004. Clin. Infect. Dis. 43:1077-1080.
7. Sorrell TC. 2001. Cryptococcus neoformans variety gattii. Med. Mycol. 39:155-168.
8. Bovers M, Hagen F, Kuramae EE, Hoogveld HL, Dromer F, St-Germain G, Boekhout T. 2008. AIDS patient death caused by novel Cryptococcus neoformans × C. gattii hybrid. Emerg. Infect. Dis. 14:1105-1108.
9. St-Germain G, Noel G, Chung KJ. 1988. Disseminated cryptococcosis due to Cryptococcus neoformans variety gattii in a Canadian patient with AIDS. Eur. J. Clin. Microbiol. Infect. Dis. 7:587-588.
10. Galanis E, Hoang L, Kibsey P, Morshed M, Phillips P. 2009. Clinical presentation, diagnosis and management of Cryptococcus gattii cases: lessons learned from British Columbia. Can. J. Infect. Dis. Med. Microbiol. 20:23-28.
11. Kidd SE, Hagen F, Tscharke RL, Huynh M, Bartlett KH, Fyfe M, Macdougall L, Boekhout T, Kwon-Chung KJ, Meyer W. 2004. A rare genotype of Cryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada). Proc. Natl. Acad. Sci. U. S. A. 101:17258-17263.
12. Galanis E, Macdougall L. 2010. Epidemiology of Cryptococcus gattii, British Columbia, Canada, 1999-2007. Emerg. Infect. Dis. 16:251-257.
13. Byrnes EJ, 3rd, Bildfell RJ, Frank SA, Mitchell TG, Marr KA, Heitman J. 2009. Molecular evidence that the range of the Vancouver Island outbreak of Cryptococcus gattii infection has expanded into the Pacific Northwest in the United States. J. Infect. Dis. 199:1081-1086.
14. Datta K, Bartlett KH, Baer R, Byrnes E, Galanis E, Heitman J, Hoang L, Leslie MJ, MacDougall L, Magill SS, Morshed MG, Marr KA, Cryptococcus gattii Working Group of the Pacific Northwest. 2009. Spread of Cryptococcus gattii into Pacific Northwest region of the United States. Emerg. Infect. Dis. 15:1185-1191.
15. Fyfe M, MacDougall L, Romney M, Starr M, Pearce M, Mak S, Mithani S, Kibsey P. 2008. Cryptococcus gattii infections on Vancouver Island, British Columbia, Canada: emergence of a tropical fungus in a temperate environment. Can. Commun. Dis. Rep. 34:1-12.
16. Chen S, Sorrell T, Nimmo G, Speed B, Currie B, Ellis D, Marriott D, Pfeiffer T, Parr D, Byth K. 2000. Epidemiology and host- and varietydependent characteristics of infection due to Cryptococcus neoformans in Australia and New Zealand. Clin. Infect. Dis. 31:499-508.
17. Cheng PY, Sham A, Kronstad JW. 2009. Cryptococcus gattii isolates from the British Columbia cryptococcosis outbreak induce less protective inflammation in a murine model of infection than Cryptococcus neoformans. Infect. Immun. 77:4284-4294.
18. de Repentigny L, Aumont F, Ripeau JS, Fiorillo M, Kay DG, Hanna Z, Jolicoeur P. 2002. Mucosal candidiasis in transgenic mice expressing human immunodeficiency virus type 1. J. Infect. Dis. 185:1103-1114.
19. Hanna Z, Kay DG, Rebai N, Guimond A, Jothy S, Jolicoeur P. 1998. Nef harbors a major determinant of pathogenicity for an AIDS-like disease induced by HIV-1 in transgenic mice. Cell 95:163-175.
20. Poudrier J, Weng X, Kay DG, Hanna Z, Jolicoeur P. 2003. The AIDSCryptococcuslike disease of CD4C/human immunodeficiency virus transgenic mice is associated with accumulation of immature CD11bHi dendritic cells. J. Virol. 77:11733-11744.
21. Poudrier J, Weng X, Kay DG, Pare G, Calvo EL, Hanna Z, Kosco- Vilbois MH, Jolicoeur P. 2001. The AIDS disease of CD4C/HIV transgenic mice shows impaired germinal centers and autoantibodies and develops in the absence of IFN-gamma and IL-6. Immunity 15:173-185.
22. Priceputu E, Rodrigue I, Chrobak P, Poudrier J, Mak TW, Hanna Z, Hu C, Kay DG, Jolicoeur P. 2005. The Nef-mediated AIDS-like disease of CD4C/human immunodeficiency virus transgenic mice is associated with increased Fas/FasL expression on T cells and T-cell death but is not prevented in Fas-, FasL-, tumor necrosis factor receptor 1-, or interleukin- 1beta-converting enzyme-deficient or Bcl2-expressing transgenic mice. J. Virol. 79:6377-6391.
23. + T cells from CD4C/HIVNef transgenic mice show enhanced activation in vivo with impaired proliferation in vitro but are dispensable for the development of a severe AIDS-like organ disease. J. Virol. 78:5244-5257.
24. Kay DG, Yue P, Hanna Z, Jothy S, Tremblay E, Jolicoeur P. 2002. Cardiac disease in transgenic mice expressing human immunodeficiency virus-1 nef in cells of the immune system. Am. J. Pathol. 161:321-335.
25. de Repentigny L, Lewandowski D, Jolicoeur P. 2004. Immunopathogenesis of oropharyngeal candidiasis in human immunodeficiency virus infection. Clin. Microbiol. Rev. 17:729-759.
26. Goupil M, Trudelle EB, Dugas V, Racicot-Bergeron C, Aumont F, Senechal S, Hanna Z, Jolicoeur P, de Repentigny L. 2009. Macrophagemediated responses to Candida albicans in mice expressing the human immunodeficiency virus type 1 transgene. Infect. Immun. 77:4136-4149.
27. +T cell phenotype and function determine the susceptibility to mucosal candidiasis in transgenic mice expressing HIV-1. J. Immunol. 177: 479-491.
28. + T cells but not polymorphonuclear leukocytes are required to limit chronic oral carriage of Candida albicans in transgenic mice expressing human immunodeficiency virus type 1. Infect. Immun. 74:2382-2391.
29. Litvintseva AP, Mitchell TG. 2009. Most environmental isolates of Cryptococcus neoformans var. grubii (serotype A) are not lethal for mice. Infect. Immun. 77:3188-3195.
30. Rivera J, Feldmesser M, Cammer M, Casadevall A. 1998. Organdependent variation of capsule thickness in Cryptococcus neoformans during experimental murine infection. Infect. Immun. 66:5027-5030.
31. Feldmesser M, Kress Y, Novikoff P, Casadevall A. 2000. Cryptococcus neoformans is a facultative intracellular pathogen in murine pulmonary infection. Infect. Immun. 68:4225-4237.
32. Feldmesser M, Tucker S, Casadevall A. 2001. Intracellular parasitism of macrophages by Cryptococcus neoformans. Trends Microbiol. 9:273-278.
33. Feldmesser M, Kress Y, Casadevall A. 2001. Dynamic changes in the morphology of Cryptococcus neoformans during murine pulmonary infection. Microbiology 147:2355-2365.
34. Hoag KA, Street NE, Huffnagle GB, Lipscomb MF. 1995. Early cytokine production in pulmonary Cryptococcus neoformans infections distinguishes susceptible and resistant mice. Am. J. Respir. Cell Mol. Biol. 13: 487-495.
35. Kleinschek MA, Muller U, Brodie SJ, Stenzel W, Kohler G, Blumenschein WM, Straubinger RK, McClanahan T, Kastelein RA, Alber G. 2006. IL-23 enhances the inflammatory cell response in Cryptococcus neoformans infection and induces a cytokine pattern distinct from IL-12. J. Immunol. 176:1098-1106.
36. Muller U, Stenzel W, Kohler G, Werner C, Polte T, Hansen G, Schutze N, Straubinger RK, Blessing M, McKenzie AN, Brombacher F, Alber G. 2007. IL-13 induces disease-promoting type 2 cytokines, alternatively activated macrophages and allergic inflammation during pulmonary infection of mice with Cryptococcus neoformans. J. Immunol. 179:5367-5377.
37. Voelz K, Lammas DA, May RC. 2009. Cytokine signaling regulates the outcome of intracellular macrophage parasitism by Cryptococcus neoformans. Infect. Immun. 77:3450-3457.
38. Gal AA, Koss MN, Hawkins J, Evans S, Einstein H. 1986. The pathology of pulmonary cryptococcal infections in the acquired immunodeficiency syndrome. Arch. Pathol. Lab. Med. 110:502-507. 39. McDonnell JM, Hutchins GM. 1985. Pulmonary cryptococcosis. Hum. Pathol. 16:121-128.
39. McDonnell JM, Hutchins GM. 1985. Pulmonary cryptococcosis. Hum. Pathol. 16:121-128.
40. Torda A, Kumar RK, Jones PD. 2001. The pathology of human and murine pulmonary infection with Cryptococcus neoformans var. gattii. Pathology 33:475-478.
41. Ngamskulrungroj P, Chang Y, Sionov E, Kwon-Chung KJ. 2012. The primary target organ of Cryptococcus gattii is different from that of Cryptococcus neoformans in a murine model. mBio 3:e00103-12. doi:10.1128 /mBio.00103-12.
42. + T cells during a pulmonary Cryptococcus neoformans infection. J. Immunol. 155:4790-4797.
43. Traynor TR, Herring AC, Dorf ME, Kuziel WA, Toews GB, Huffnagle GB. 2002. Differential roles of CC chemokine ligand 2/monocyte chemotactic protein-1 and CCR2 in the development of T1 immunity. J. Immunol. 168:4659-4666.
44. Osterholzer JJ, Chen GH, Olszewski MA, Zhang YM, Curtis JL, Huffnagle GB, Toews GB. 2011. Chemokine receptor 2-mediated accumulation of fungicidal exudate macrophages in mice that clear cryptococcal lung infection. Am. J. Pathol. 178:198-211.
45. Osterholzer JJ, Curtis JL, Polak T, Ames T, Chen GH, McDonald R, Huffnagle GB, Toews GB. 2008. CCR2 mediates conventional dendritic cell recruitment and the formation of bronchovascular mononuclear cell infiltrates in the lungs of mice infected with Cryptococcus neoformans. J. Immunol. 181:610-620.
46. + lung dendritic cells in response to fungal infection results from the CCR2-mediated recruitment and differentiation of Ly-6Chigh monocytes. J. Immunol. 183:8044-8053.
47. Qiu Y, Zeltzer S, Zhang Y, Wang F, Chen GH, Dayrit J, Murdock BJ, Bhan U, Toews GB, Osterholzer JJ, Standiford TJ, Olszewski MA. 2012. Early induction of CCL7 downstream of TLR9 signaling promotes the development of robust immunity to cryptococcal infection. J. Immunol. 188:3940-3948.
48. Huffnagle GB, Traynor TR, McDonald RA, Olszewski MA, Lindell DM, Herring AC, Toews GB. 2000. Leukocyte recruitment during pulmonary Cryptococcus neoformans infection. Immunopharmacology 48:231-236.
49. Huffnagle GB, Strieter RM, McNeil LK, McDonald RA, Burdick MD, Kunkel SL, Toews GB. 1997. Macrophage inflammatory protein-1alpha (MIP-1alpha) is required for the efferent phase of pulmonary cellmediated immunity to a Cryptococcus neoformans infection. J. Immunol. 159:318-327.
50. Huffnagle GB, Toews GB, Burdick MD, Boyd MB, McAllister KS, McDonald RA, Kunkel SL, Strieter RM. 1996. Afferent phase production of TNF-alpha is required for the development of protective T cell immunity to Cryptococcus neoformans. J. Immunol. 157:4529-4536.
51. Kawakami K, Tohyama M, Teruya K, Kudeken N, Xie Q, Saito A. 1996. Contribution of interferon-gamma in protecting mice during pulmonary and disseminated infection with Cryptococcus neoformans. FEMS Immunol. Med. Microbiol. 13:123-130.
52. Arora S, Hernandez Y, Erb-Downward JR, McDonald RA, Toews GB, Huffnagle GB. 2005. Role of IFN-gamma in regulating T2 immunity and the development of alternatively activated macrophages during allergic bronchopulmonary mycosis. J. Immunol. 174:6346-6356.
53. Retini C, Vecchiarelli A, Monari C, Tascini C, Bistoni F, Kozel TR. 1996. Capsular polysaccharide of Cryptococcus neoformans induces proinflammatory cytokine release by human neutrophils. Infect. Immun. 64: 2897-2903.
54. Curtis JL, Huffnagle GB, Chen GH, Warnock ML, Gyetko MR, Mc- Donald RA, Scott PJ, Toews GB. 1994. Experimental murine pulmonary cryptococcosis. Differences in pulmonary inflammation and lymphocyte recruitment induced by two encapsulated strains of Cryptococcus neoformans. Lab. Invest. 71:113-126.
55. Voelz K, May RC. 2010. Cryptococcal interactions with the host immune system. Eukaryot. Cell 9:835-846.
56. Okagaki LH, Strain AK, Nielsen JN, Charlier C, Baltes NJ, Chretien F, Heitman J, Dromer F, Nielsen K. 2010. Cryptococcal cell morphologyaffects host cell interactions and pathogenicity. PLoS Pathog. 6:e1000953. doi:10.1371/journal.ppat.1000953.
57. Zaragoza O, Garcia-Rodas R, Nosanchuk JD, Cuenca-Estrella M, Rodriguez- Tudela JL, Casadevall A. 2010. Fungal cell gigantism during mammalian infection. PLoS Pathog. 6:e1000945. doi:10.1371/journal.ppat.1000945.
58. Okagaki LH, Nielsen K. 2012. Titan cells confer protection from phagocytosis in Cryptococcus neoformans infections. Eukaryot. Cell 11:820-826.
59. Casadevall A. 2010. Cryptococci at the brain gate: break and enter or use a Trojan horse? J. Clin. Invest. 120:1389-1392.
60. Hernandez Y, Arora S, Erb-Downward JR, McDonald RA, Toews GB, Huffnagle GB. 2005. Distinct roles for IL-4 and IL-10 in regulating T2 immunity during allergic bronchopulmonary mycosis. J. Immunol. 174: 1027-1036.
61. Kawakami K, Hossain Qureshi M, Zhang T, Koguchi Y, Xie Q, Kurimoto M, Saito A. 1999. Interleukin-4 weakens host resistance to pulmonary and disseminated cryptococcal infection caused by combined treatment with interferon-gamma-inducing cytokines. Cell. Immunol. 197:55-61.
62. Guillot L, Carroll SF, Homer R, Qureshi ST. 2008. Enhanced innate immune responsiveness to pulmonary Cryptococcus neoformans infection is associated with resistance to progressive infection. Infect. Immun. 76:4745-4756.
63. + T cells in the protective inflammatory response to a pulmonary cryptococcal infection. J. Leukoc. Biol. 55:35-42.
64. + T cells. J. Exp. Med. 173:793-800.
65. Huffnagle GB, Yates JL, Lipscomb MF. 1991. T cell-mediated immunity in the lung: a Cryptococcus neoformans pulmonary infection model using SCID and athymic nude mice. Infect. Immun. 59:1423-1433.
66. Wang JP, Lee CK, Akalin A, Finberg RW, Levitz SM. 2011. Contributions of the MyD88-dependent receptors IL-18R, IL-1R, and TLR9 to host defenses following pulmonary challenge with Cryptococcus neoformans. PLoS One 6:e26232. doi:10.1371/journal.pone.0026232.
67. Mogensen EG, Janbon G, Chaloupka J, Steegborn C, Fu MS, Moyrand F, Klengel T, Pearson DS, Geeves MA, Buck J, Levin LR, Muhlschlegel FA. 2006. Cryptococcus neoformans senses CO2 through the carbonic anhydrase Can2 and the adenylyl cyclase Cac1. Eukaryot. Cell 5:103-111.
68. Swingler S, Zhou J, Swingler C, Dauphin A, Greenough T, Jolicoeur P, Stevenson M. 2008. Evidence for a pathogenic determinant in HIV-1 Nef involved in B cell dysfunction in HIV/AIDS. Cell Host Microbe 4:63-76.
69. Jung WH, Sham A, Lian T, Singh A, Kosman DJ, Kronstad JW. 2008. Iron source preference and regulation of iron uptake in Cryptococcus neoformans. PLoS Pathog. 4:e45. doi:10.1371/journal.ppat.0040045.
70. Lian T, Simmer MI, D'Souza CA, Steen BR, Zuyderduyn SD, Jones SJ, Marra MA, Kronstad JW. 2005. Iron-regulated transcription and capsule formation in the fungal pathogen Cryptococcus neoformans. Mol. Microbiol. 55:1452-1472.
71. Osterholzer JJ, Milam JE, Chen GH, Toews GB, Huffnagle GB, Olszewski MA. 2009. Role of dendritic cells and alveolar macrophages in regulating early host defense against pulmonary infection with Cryptococcus neoformans. Infect. Immun. 77:3749-3758.
72. Reardon CC, Kim SJ, Wagner RP, Koziel H, Kornfeld H. 1996. Phagocytosis and growth inhibition of Cryptococcus neoformans by human alveolar macrophages: effects of HIV-1 infection. AIDS 10:613-618.
73. Ieong MH, Reardon CC, Levitz SM, Kornfeld H. 2000. Human immunodeficiency virus type 1 infection of alveolar macrophages impairs their innate fungicidal activity. Am. J. Respir. Crit. Care Med. 162:966-970.
74. Cameron ML, Granger DL, Matthews TJ, Weinberg JB. 1994. Human immunodeficiency virus (HIV)-infected human blood monocytes and peritoneal macrophages have reduced anticryptococcal activity whereas HIV-infected alveolar macrophages retain normal activity. J. Infect. Dis. 170:60-67.
75. Harrison TS, Kornfeld H, Levitz SM. 1995. The effect of infection with human immunodeficiency virus on the anticryptococcal activity of lymphocytes and monocytes. J. Infect. Dis. 172:665-671.
76. Harrison TS, Levitz SM. 1997. Mechanisms of impaired anticryptococcal activity of monocytes from donors infected with human immunodeficiency virus. J. Infect. Dis. 176:537-540.
77. Kronstad JW, Attarian R, Cadieux B, Choi J, D'Souza CA, Griffiths EJ, Geddes JM, Hu G, Jung WH, Kretschmer M, Saikia S, Wang J. 2011. Expanding fungal pathogenesis: Cryptococcus breaks out of the opportunistic box. Nat. Rev. Microbiol. 9:193-203.